...Unidentified 1 We're going with our next company presenter at the BFA annual healthcare conference. I'm pleased to be introducing Roy Vant and Chief Executive Officer Matt Glein. My name is Jason Gerberry. I cover Smidcap Biotech and Specialty Pharma, and I'm joined by my colleague, Chi Fong as well. Both of us collectively cover, Muna and Roy Vance, and so. This is a great opportunity, I think, to have a discussion around a lot of the key assets that funnel up into the Royant umbrella. Awesome. So great. Unidentified 2 Thanks so much for having me. It's great to be here. I appreciate it. Yeah. Unidentified 1 So, maybe we can start with just some of the recent, changes as it pertains to the aminovant and, what that ultimately means from a development perspective, hyper focus, within certain assets within, aminovan, within the portfolio, and then we'll dig down a little deeper from there. Sure, yeah. Unidentified 2 Perfect. Look, I think the changes you're referring to. We've had a portfolio...
